Skip to main content
. 2016 Feb 24;7(10):10976–10989. doi: 10.18632/oncotarget.7686

Table 3. The comparison between HGK levels in T cells and IL-6-producing T cells from IGT and T2D patients.

Patient HGK levels (fold) IL-6-producing T (%) BMI
T2D #1 0.25 13.4 22.9
T2D #2 0.08 15.70 30.5
T2D #3 0.04 14.00 22.1
T2D #4 0.1 13.90 23.3
T2D #5 0.29 ND 22.2
T2D #6 0.01 37.50 21.9
T2D #7 0.52 10.40 26.8
T2D #8 0.14 11.80 22.6
T2D #9 0.11 26.80 22.2
T2D #10 0.62 10.00 26.6
T2D #11 2.19 9.00 23.9
IGT #1 0.97 15.00 28.1
IGT #2 3.69 2.49 25.2
IGT #3 0.53 11.80 21.7
IGT #4 0.25 16.70 27.5
HC #1 1.00 9.80 21.8
HC #2 1.09 10.00 21.2
HC #3 3.72 3.36 25.3
HC #4 1.00 6.09 21.8
HC #5 1.00 4.88 20.5
HC #6 0.81 9.00 28.8
HC #7 1.00 7.38 20.7
HC #8 1.53 4.57 20.2
HC #9 1.00 3.31 25.3

Shown are the level of HGK expression and the frequency of IL-6-producing T cells in individual IGT or T2D patients whose immunoblot data were available. The frequency of IL-6-producing T cells for one patient (#5) was not determined (ND). Fold denotes HGK levels of individual samples relative to that of the first healthy control on each membrane (Figure 1A).